The size of the Genome Editing Market in Europe was worth USD 0.89 billion in 2020 and estimated to be growing at a CAGR of 14.13% to reach USD 1.73 billion by 2025 during the forecast period. The genome editing market of the European region is mainly driven by factors like an increase in advancements, technological advancements in genomics. The increasing occurrence rate of chronic diseases and growing funds by the government and private organizations help improve the genomics project. Opportunities for consumer genomics are considered to have a positive impact on the European genome editing market growth in the forthcoming years.
Genome editing is a way of making specific changes to the DNA of a cell or organism. By editing the genome of an organism, its characteristics can be changed. An approach commonly used in biological research is modifying the DNA of an organism and observing its impact. Genome Editing uses a particular type of enzyme called an engineered nuclease, which cuts the genome in the desired place. The cut part will naturally be repaired by the cell, which can be manipulated to make changes to the DNA in that location. The changes can be small wherein just a tiny function of that section of DNA is affected or can be complete removal of a part of DNA. It is also possible to insert a section of DNA into the genome as and when it arises.
The key drivers of the Europe Genome Editing Market include the applications of DNA editing in therapeutics, the use of the technology in disease eradication, and the alteration of pathogen targets in the host. The ability of genome editing therapies to provide a noteworthy improvement to healthcare services. Other factors affecting the growth include improved efficacy and reduced side effects of disease treatment.
Despite the multitude of uses, the market still gets hampered by factors such as the high costs associated with genome editing, the equipment used, and the ethical concerns regarding genome editing, which several NGOs brought up.
This research report has been segmented and sub-segmented into the following categories:
Regional Analysis
Globally, the European region is currently occupying the second position in the leading majority of the shares. The UK leads the genome editing market of this region as the upgraded technologies are carried out at the biotechnological companies, including the research and development producing products for genome editing. UK based company; Horizon Discovery has invented cell lines where the industry has used the potentiality of the AAV's to increase the cell's fidelity DNA repair.
Germany is witnessed to grow with the highest CAGR during the forecast period as the genome editing market's extent is a growing number of applications and its diseases. Germany has a considerable range in treating different cancers, genetically affected cells, and agents of infectious diseases like parasites, viruses, bacteria, and many more. Favorable government policies include research activities, which include the discovery of new drugs and therapies into the market by the specialized key players.
France, Italy, and Spain are likely to showcase promising growth opportunities in the coming years.
Companies playing a pivotal role in the Europe Genome Editing Market profiled in this report are Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Application
5.1.1 Introduction
5.1.2 Cell Line Engineering
5.1.3 Animal Genetic Engineering
5.1.4 Plant Genetic Engineering
5.1.5 Y-o-Y Growth Analysis, By Application
5.1.6 Market Attractiveness Analysis, By Application
5.1.7 Market Share Analysis, By Application
5.2 Technology
5.3.1 Introduction
5.3.2 CRISPR
5.3.3 TALEN
5.3.4 ZFN
5.3.5 Antisense
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.3 End User
5.2.1 Introduction
5.2.2 Biotechnological & Pharmaceutical Companies
5.2.3 Academic and Government Research Institutes
5.2.4 Contract Research Organizations
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Technology
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Technology
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Technology
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five Analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Thermo Fisher Scientific
8.1.1 Overview
8.1.2 Application Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck KGAA
8.3 Horizon Discovery Group Plc
8.4 Genscript Biotech Corporation
8.5 Sangamo Biosciences
8.6 Integrated DNA Technologies
8.7 Lonza Group Ltd
8.8 New England Biolabs
8.9 Origene Technologies
8.10 Transposagen Biopharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
Appendix
Related Reports
Feb 2020
